# EDGAR Filing Document

**Accession Number:** 0001739104
**File Stem:** 0001739104-26-000018
**Filing Date:** 2026-4
**Character Count:** 4165
**Document Hash:** 15a2da8ad8552a8b77ffe4cf6415c7ea
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001739104-26-000018.hdr.sgml**: 20260408

**ACCESSION NUMBER**: 0001739104-26-000018

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20260408

**DATE AS OF CHANGE**: 20260408

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Elanco Animal Health Inc
- **CENTRAL INDEX KEY:** 0001739104
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 825497352
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38661
- **FILM NUMBER:** 26846853

**BUSINESS ADDRESS:**
- **STREET 1:** 450 ELANCO CIRCLE
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46221
- **BUSINESS PHONE:** 877-352-6261

**MAIL ADDRESS:**
- **STREET 1:** 450 ELANCO CIRCLE
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46221

![](noticeofmlingf001.jpg)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 Elanco Animal Health Incorporated (Name of registrant as specified in its charter) (Name of person(s) filing proxy statement, if other than the registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.

------

![](noticeofmlingf002.jpg)

Your Vote Counts! \*Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V88216-P46769 ELANCO ANIMAL HEALTH INCORPORATED 450 ELANCO CIRCLE INDIANAPOLIS, IN 46221 ELANCO ANIMAL HEALTH INCORPORATED 2026 Annual Meeting Vote by May 20, 2026 11:59 PM ET You invested in ELANCO ANIMAL HEALTH INCORPORATED and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on May 21, 2026. Vote Virtually at the Meeting\* May 21, 2026 8:00 a.m. Eastern Time Virtually at: www.virtualshareholdermeeting.com/ELAN2026 Get informed before you vote View the Notice and Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 7, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

------

![](noticeofmlingf003.jpg)

Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings". Voting Items Board Recommends V88217-P46769 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. Election of two Class I director nominees and three Class II director nominees: Class I Nominees: 1a. Kapila Anand For 1b. Paul Herendeen For Class II Nominees: 1c. Michael Harrington For 1d. Lawrence Kurzius For 1e. Kirk McDonald For 2. Ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for 2026. For 3. Advisory vote on the compensation of the company's named executive officers. For

------